NCT02693535 2026-03-19
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
Clinical Trials
32 trialsNCT04039230 2026-03-16
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Massachusetts General Hospital
Phase 1/2 Active not recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT04693468 2026-03-13
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03968406 2026-03-11
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04170946 2026-03-05
Talazoparib
University Health Network, Toronto
Phase 1 Recruiting
NCT04511039 2026-03-02
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT03974217 2026-02-25
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT04901702 2026-02-09
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT04734730 2026-01-28
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT02286687 2026-01-02
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05873192 2025-12-23
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04019327 2025-12-15
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03672773 2025-11-10
TRIO-US L-07
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT06844383 2025-10-29
TALENT
Prostate Cancer Clinical Trials Consortium
Phase 2 Recruiting
NCT04678362 2025-09-22
TALASUR
Centre Francois Baclesse
Phase 2 Recruiting
NCT04486352 2025-09-04
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT04756765 2025-08-17
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
Stanford University
Phase 2 Withdrawn
NCT06762808 2025-08-15
Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03990896 2025-08-07
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Massachusetts General Hospital
Phase 2 Recruiting
NCT05035745 2025-07-25
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
National University Hospital, Singapore
Phase 1/2 Recruiting
NCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05071937 2025-06-22
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT04740190 2025-06-11
TAC-GReD
The University of Hong Kong
Phase 2 Completed
NCT04849364 2025-05-31
PERSEVERE
Hoosier Cancer Research Network
Phase 2 Terminated
NCT05101551 2025-05-29
PARPAML
Stanford University
Phase 1 Recruiting
NCT04337970 2025-05-28
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03964532 2025-05-21
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Georgetown University
Phase 1/2 Active not recruiting
NCT04332744 2025-05-11
ZZ-First
MedSIR
Phase 2 Completed
NCT04846478 2025-04-17
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT04892693 2025-04-17
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency
Seoul National University Hospital
Phase 2 Recruiting